Subjective well-being in schizophrenia: A randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER)

European Neuropsychopharmacology

Volumn 23, Issue 10, 2013, Pages 1257-1269

  Naber, Dieter ^a   Peuskens, Joseph ^b   Schwarzmann, Nadine ^c   Goltz, Marc ^c   Krüger, Hagen ^c   Lambert, Martin ^a   Maria Haro, Josep ^d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ASTRAZENECA   (United Kingdom)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Quality of life; Quetiapine XR; Risperidone; Schizophrenia; Subjective well being

Indexed keywords

PROLACTIN; QUETIAPINE; RISPERIDONE;

ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; ASTHENIA; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOMOTOR DISORDER; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; SWN K TOTAL SCORE; TENSION; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN; WELLBEING;

QUALITY OF LIFE; QUETIAPINE XR; RISPERIDONE; SCHIZOPHRENIA; SUBJECTIVE WELL-BEING;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DRUG MONITORING; DRUG RESISTANCE; EXTRAPYRAMIDAL TRACTS; FEMALE; HUMANS; INCIDENCE; INTENTION TO TREAT ANALYSIS; LOST TO FOLLOW-UP; MALE; MIDDLE AGED; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THERAPEUTIC EQUIVALENCY;

EID: 84884284516     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.07.006     Document Type: Article

References (46)

1. Addington D., Addington J., Atkinson M. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr. Res. 1996, 19:205-212.
2. Addington D., Addington J., Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr. Res. 1994, 11:239-244.
3. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability and validity of a Depression Rating Scale for schizophrenics. Schizophr. Res. 1992, 6:201-208.
4. Andreasen N.C., Carpenter W.T., Kane J.M., Lasser R.A., Marder S.R., Weinberger D.R. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 2005, 162:441-449.
5. Bellack A.S. Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr. Bull. 2006, 32:432-442.
6. Böhning D., Sarol J. Estimating risk difference in multicenter studies under baseline-risk heterogeneity. Biometrics 2000, 56:304-308.
7. Brooks R., Rabin R., De Charro F. The measurement and valuation of health status using EQ-5D: a European perspective 2003, Kluwer Academic Publishers, Dordrecht, The Netherlands.
8. Compton M.T., Miller A.H. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol. Bull. 2002, 36:143-164.
9. Correll C.U. What are we looking for in new antipsychotics?. J. Clin. Psychiatry 2011, 72(Suppl. 1):9-13.
10. de Haan L., Lavalaye J., Linszen D., Dingemans P.M., Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am. J. Psychiatry 2000, 157:1019-1020.
11. de Haan L., Nimwegen L.v., Amelsvoort T.v., Dingemans P., Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008, 41:125-128.
12. de Haan L., van Bruggen M., Lavalaye J., Booij J., Dingemans P.M., Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am. J. Psychiatry 2003, 160:303-309.
13. Emsley R., Chiliza B., Asmal L., Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr. Opin. Psychiatry 2011, 24:114-121.
14. Guy, W., 1976. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology, Washington, DC: US Department of Health, Education and Welfare, pp. 218-222.
15. Haro J.M., Kamath S.A., Ochoa S., Novick D., Rele K., Fargas A., Rodríguez M.J., Rele R., Orta J., Kharbeng A., Araya S., Gervin M., Alonso J., Mavreas V., Lavrentzou E., Liontos N., Gregor K., Jones P.B. The Clinical Global Impression-Schizophrenia Scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. 2003, (Suppl.):16-23.
16. Jones P.B., Barnes T.R., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch. Gen. Psychiatry 2006, 63:1079-1087.
17. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., Schimmelmann B.G., Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J. Clin. Psychiatry 2007, 68:75-80.
18. Karow A., Moritz S., Lambert M., Schoder S., Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005, 38:320-326.
19. Lambert M., Karow A., Leucht S., Schimmelmann B.G., Naber D. Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin. Neurosci. 2010, 12:393-407.
20. Lambert M., Naber D., Eich F.X., Schacht M., Linden M., Schimmelmann B.G. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr. Scand. 2007, 115:106-113.
21. Lambert M., Naber D., Karow A., Huber C.G., Köhler J., Heymann J., Schimmelmann B.G. Subjective wellbeing under quetiapine treatment: effect of diagnosis, mood state, and anxiety. Schizophr. Res. 2009, 110:72-79.
22. Lambert M., Naber D., Schacht A., Wagner T., Hundemer H.P., Karow A., Huber C.G., Suarez D., Haro J.M., Novick D., Dittmann R.W., Schimmelmann B.G. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr. Scand. 2008, 118:220-229.
23. Lambert M., Schimmelmann B.G., Naber D., Eich F.X., Schulz H., Huber C.G., Karow A. Early and delayed antipsychotic response and prediction of outcome in 528 severely impaired patients with schizophrenia treated with amisulpride. Pharmacopsychiatry 2009, 42:277-283.
24. Lambert M., Schimmelmann B.G., Naber D., Schacht A., Karow A., Wagner T., Czekalla J. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J. Clin. Psychiatry 2006, 67:1690-1697.
25. Lambert M., Schimmelmann B.G., Schacht A., Karow A., Wagner T., Wehmeier P.M., Huber C.G., Hundemer H.P., Dittmann R.W., Naber D. Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years. Schizophr. Res. 2009, 107:165-172.
26. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 1987, (Suppl 334):1-100.
27. Mizrahi R., Rusjan P., Agid O., Graff A., Mamo D.C., Zipursky R.B., Kapur S. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. Am. J. Psychiatry 2007, 164:630-637.
28. Mullen J., Jibson M.D., Sweitzer D. A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin. Ther. 2001, 23:1839-1854.
29. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int. Clin. Psychopharmacol. 1995, 10(Suppl. 3):133-138.
30. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R., Andresen B. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr. Res. 2001, 50:79-88.
31. Naber D., Riedel M., Klimke A., Vorbach E.U., Lambert M., Kühn K.U., Bender S., Bandelow B., Lemmer W., Moritz S., Dittmann R.W. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr. Scand. 2005, 111:106-115.
32. Narvaez J.M., Twamley E.W., McKibbin C.L., Heaton R.K., Patterson T.L. Subjective and objective quality of life in schizophrenia. Schizophr. Res. 2008, 98:201-208.
33. Nyberg S., Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties. Eur. Psychiatry 2010, 25(Suppl. 1):1-27.
34. Perez V., Cañas F., Tafalla M. A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. Int. Clin. Psychopharmacol. 2008, 23:138-149.
35. Resnick S.G., Fontana A., Lehman A.F., Rosenheck R.A. An empirical conceptualization of the recovery orientation. Schizophr. Res. 2005, 75:119-128.
36. Sajatovic M., Mullen J.A., Sweitzer D.E. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J. Clin. Psychiatry 2002, 63:1156-1163.
37. Sands J.R., Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr. Bull. 1999, 25:157-171.
38. Schennach-Wolff R., Seemüller F., Obermeier M., Messer T., Laux G., Pfeiffer H., Naber D., Schmidt L.G., Gaebel W., Klosterkötter J., Heuser I., Maier W., Lemke M.R., Rüther E., Buchkremer G., Gastpar M., Jäger M., Möller H.J., Riedel M. Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders. Eur. Psychiatry 2011, 26:284-292.
39. Schimmelmann B.G., Paulus S., Schacht M., Tilgner C., Schulte-Markwort M., Lambert M. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J. Child Adolescent Psychopharmacol. 2005, 15:249-258.
40. Silva de Lima M., de Jesus Mari J., Breier A., Maria Costa A., Pondé de Sena E., Hotopf M. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J. Clin. Psychiatry 2005, 66:831-838.
41. Tohen M., Hennen J., Zarate C.M., Baldessarini R.J., Strakowski S.M., Stoll A.L., Faedda G.L., Suppes T., Gebre-Medhin P., Cohen B.M. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am. J. Psychiatry 2000, 157:220-228.
42. Tomotake M. Quality of life and its predictors in people with schizophrenia. J. Med. Invest. 2011, 58:167-174.
43. Van Putten T. Why do schizophrenic patients refuse to take their drugs?. Arch. Gen. Psychiatry 1974, 31:67-72.
44. Vothknecht S., Schoevers R.A., de H.L. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review. Aust. N. Z. J. Psychiatry 2011, 45:182-192.
45. Wehmeier P.M., Kluge M., Schacht A., Helsberg K., Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr. Res. 2007, 91:178-186.
46. Wehmeier P.M., Kluge M., Schacht A., Helsberg K., Schreiber W., Schimmelmann B.G., Lambert M. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. J. Psychiatr. Res. 2008, 42:676-683.